Citrate salt of an indole derivative and its pharmaceutical use

Details Citrate salt of an indole derivative and its pharmaceutical use Citrate salt of an indole derivative and its pharmaceutical use

2011-08-30

2011-08-30

Anderson, Rebecca (Department: 1626)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

C544S124000

Reexamination Certificate

active

08008294

ABSTRACT:
The salt, the 2-hydroxy-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]1H-indole-5-carbonitrile citrate, a process for its preparation, pharmaceutical formulations containing it and the use of it in therapy, and particularly in the therapy of GSK3 related conditions and disorders.

REFERENCES:
patent: 7399780 (2008-07-01), Berg et al.
patent: 2007/0203137 (2007-08-01), Sebhatu et al.
patent: 200309588 (2008-10-01), None
patent: 02085897 (2002-10-01), None
patent: 03082853 (2003-10-01), None
patent: 2005027823 (2005-03-01), None
patent: 2006070195 (2006-07-01), None
Berge et al., “Pharmaceutical Salts”, J Pharm Sci 66(1):1-19, 1977.
Bell, N.H., “Advances in the Treatment of Osteoporosis”, Current Drug Targets—Immune, Endocrine & Metabolic Disorders, 2001, vol. 1, pp. 93-102.
Bhat, R. et al, “Regulation and localization of tyrosine etc”, PNAS, Sep. 26, 2000, vol. 97, No. 20, pp. 11074-11079.
Cline, G.W. et al, “Effects of a Novel Glycogen Synthase Kinase-3 Inhibitor etc.”, Diabetes, Oct. 2002, vol. 51, pp. 2903-2910.
Cotter, D. et al, “Abnormalities of Wnt signalling in schizophrenia—evidence for neurodevelopmental abnormality”, NeuroReport 1998, vol. 9, No. 7, pp. 1379-1383.
Gat, U. et al, “De Novo Hair Follicle Morphogenesis and Hair Tumors etc.”, Cell, Nov. 25, 1998, vol. 95, pp. 605-614.
Gould, T. et al, “In Vivo Evidence in the Brain for Lithium Inhibition of Glycogen Synthase Kinase-3”, Neuropsychopharmacology 2004, vol. 29, pp. 32-38.
Hoshi, M. et al, “Regulation of mitochondrial pyruvate dehydrogenase activity etc.”, Proc. Natl. Acad. Sci. USA, Apr. 1996, vol. 93, pp. 2719-2723.
Imahori, K. et al, “Physiology and Pathology of Tau Protein Kinases in Relation to Alzheimer's Disease”, J. Biochem. 1997, vol. 121 No. 2, pp. 179-188.
Jope, R.S. et al, “Glycogen Synthase Kinase-3 (GSK3): Inflammation, Diseases, and Therapeutics”, Neurochem. Res., Aug. 30, 2006, DOI 10.1007/s11064-006-9128-5.
Klein, P. et al, “A molecular mechanism for the effect of lithium on development”, PNAS, Aug. 1996, vol. 93, pp. 8455-8459.
Kozlovsky, N. et al, “Low GSK-3beta Immunoreactivity in Postmortem Frontal Cortex of Schizophrenic Patients”, Am. J. Psychiatry, May 2000, 157:5, pp. 831-833.
Li, Xiaohua, et al, “Regulation of mouse brain glycogen synthase kinase-3 etc.”, Int. J. of Neuropsychopharmacol, Feb. 2007; 10(1), pp. 7-19. Epub May 4, 2006, doi:10.1017/S1461145706006547.
Martin, M. et al., “Toll-like receptor-mediated cytokine production etc”, Nature Immunology, Aug. 2005, vol. 6, No. 8, pp. 777-784.
Nikoulina, S. et al, “Potential Role of Glycogen Synthase Kinase-3 etc”, Diabetes, Feb. 2000, vol. 49, pp. 263-271.
O'Brian, W.T. et al, “Glycogen Synthase Kinase etc”, The Journal of Neuroscience, Jul. 28, 2004, 24(30), pp. 6791-6798.
Ring, D.B. et al, “Selective Glycogen Synthase Kinase 3 Inhibitors etc.”, Diabetes, Mar. 2003, vol. 52, pp. 588-595.
Shusei, et al., “Solid Dispersing Element”, Patent Abstracts of Japan, Publication No. 2000-309588, Taisho Pharmaceut Co. Ltd., Filed Apr. 29, 1999.
Stambolic, V. et al, “Lithium inhibits glycogen synthase kinase-3 activity etc.”, Current Biology 1996, vol. 6, No. 12, pp. 1664-1668.
Szczepankiewicz, A. et al, “Association Analysis of the GSK-3beta T-50C Gene Polymorphism with Schizophrenia and Bipolar Disorder”, Neuropsychobiology, 2006, 53, pp. 51-56.
Su, Y. et al, “Lithium, a Common Drug for Bipolar Disorder Treatment, Regulates etc.”, Biochemistry 2004, vol. 43, pp. 6899-6908.
Tobias, J.H., et al, “Novel therapeutic targets in osteoporosis”, Expert Opinion Therapeutic Targets 2002, 6(1), pp. 41-56.
Vijayaraghavan et al, “A Role for Phosphorylation of Glycogen Synthase etc”, Biology of Reproduction, 2000, 62, pp. 1647-1654.
Patent Abstracts of Japan, Publication No. 2000-309588, Nov. 7, 2000, Taisho Pharmaceut Co. LTD.

Affiliated with

Also associated with

Rating

Citrate salt of an indole derivative and its pharmaceutical use does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Citrate salt of an indole derivative and its pharmaceutical use, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Citrate salt of an indole derivative and its pharmaceutical use will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2751497